SOURCES SOUGHT
66 -- nucliSENS lysis Buffer, 2ml, Easy Q HIV-1 2.0 kit
- Notice Date
- 7/23/2012
- Notice Type
- Sources Sought
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2012-49233
- Archive Date
- 8/14/2012
- Point of Contact
- Tayaria L Smith, Phone: 7704882797
- E-Mail Address
-
gqq4@cdc.gov
(gqq4@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- Notice of Intent PR# 2012-49233 The Division of Global AIDS Program of the Centers for Disease Control and Prevention intends to award a sole source, firm fixed price contract, in accordance with FAR 13, using simplified acquisition procedures, to Biomerieux Inc, 100 Rodolphe St, Durham NC, 27712-9402. Biomeriux will provide 61 of their NuclinSENS Lysis Buffer 2ml kits along with 61 Easy Q HIV-1 v2.1 RUO Test kits, which is an "in vitro real-time NASBA assay for the quantification of HIV-1 RNA in HIV-1 infected individuals", this shall be delivered with buffers, disposables and silica. The product numbers are 285007 and 200292. Biomeriux, Inc appears to be the sole provider. No Request for Quotes (RFQ) will be issued based upon this Notice of Intent. This advertisements ends in 7 days according to FAR 5.203 (A). Any interested companies are welcome to submit their ability to provide these items via e-mail, gqq4@cdc.gov. Please include reference number (2012-49233). Please respond by July 23, 2012.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2012-49233/listing.html)
- Place of Performance
- Address: Atlanta, Georgia, United States
- Record
- SN02812474-W 20120725/120724000143-1a0c7e6f5162411ceb24af836698c6cb (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |